November 25, 2019

David McClung
Chief Financial Officer
BioCardia, Inc.
125 Shoreway Road, Suite B
San Carlos, California 94070

       Re: BioCardia, Inc.
           Form 10-K for the Fiscal Year Ended December 31, 2018
           Filed April 2, 2019
           File No. 000-21419

Dear Mr. McClung:

      We have reviewed your filing and have the following comment. In our
comment, we
may ask you to provide us with information so we may better understand your
disclosure.

       Please respond to the comment within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to the comment, we may have additional
comments.

Form 10-K for the Fiscal Year Ended December 31, 2018

ITEM 1. BUSINESS
Cell Processing and Cell Delivery Product Platforms, page 6

1.    You disclose that you "believe the Helix biotherapeutic delivery system
is the world's
      safest and most efficient platform for cardiac therapeutic delivery."
Although you
      disclose the Helix system has received regulatory approval for commercial
use in Europe,
      it has only received FDA approval for investigational use in the United
States. Because
      the Helix system has not received marketing approval from the FDA, it is
premature to
      suggest or imply that it is safe or effective. Please provide to us draft
disclosure for future
      periodic filings revising this or other similar statements accordingly.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
 David McClung
BioCardia, Inc.
November 25, 2019
Page 2

       You may contact Rolf Sundwall at 202-551-3105 or Sasha Parikh at
202-551-3627 if you
have questions.



FirstName LastNameDavid McClung                         Sincerely,
Comapany NameBioCardia, Inc.
                                                        Division of Corporation
Finance
November 25, 2019 Page 2                                Office of Life Sciences
FirstName LastName